Pemetrexed Dipotassium Injection, Powder, Lyophilized, For Solution
Product Images NDC 83831-111

15 FDA label images from Avyxa Pharma, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pemetrexed Dipotassium (NDC 83831-111). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avyxa Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 01)

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 01)
Chemical structure of pemetrexed dipotassium, showing its molecular configuration including potassium carboxylate groups and hydration with seven water molecules (.7H2O).*
FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 02)

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 02)
A survival curve chart comparing two treatment groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The graph shows survival probability on the vertical axis and survival time in months on the horizontal axis, with patient counts at risk listed beneath the timeline.*
FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 03)

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 03)
A Kaplan-Meier survival curve comparing survival probability over time (in months) between two groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The chart includes a table below showing the number of patients at risk at various time points for each treatment group.*
FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 04)

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 04)
A survival probability curve chart comparing two treatment groups over 30 months: Pemetrexed + Cisplatin (PC) shown with a solid line and Gemcitabine + Cisplatin (GC) shown with a dotted line. The x-axis represents survival time in months, and the y-axis represents survival probability. Below the chart is a table indicating the number of patients at risk at various time points for each group.*
FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 05)

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 05)
A Kaplan-Meier survival curve chart comparing survival probability over time (months) between patients treated with Pemetrexed and those given a placebo. The graph includes survival probability on the Y-axis and survival time in months on the X-axis, with a table below indicating the number of patients at risk at various time points for both groups.*
FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 06)

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 06)
A Kaplan-Meier survival curve showing survival probability over survival time in months for two groups: pemetrexed and placebo. The graph includes a table beneath indicating the number of patients at risk at various time points for each group. The pemetrexed group is represented by a solid line, and the placebo group by a dotted line.*
FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 07)

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 07)
A Kaplan-Meier survival curve chart comparing survival probability over time (in months) between patients treated with pemetrexed and those given a placebo. The chart includes a table below showing the number of patients at risk at various time points for each group.*
FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 08)

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 08)
A Kaplan-Meier survival curve graph showing survival probability over time (months) comparing Pemtrexed and Placebo groups. The solid line represents Pemtrexed, and the dotted line represents Placebo. Below the graph, a table lists patient counts at risk for each group at various time points from 0 to 33 months.*
FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 09)

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 09)
A Kaplan-Meier survival curve comparing survival probability over time in months between two treatment groups: Pemetrexed + Cisplatin (solid line) and Cisplatin alone (dotted line). The chart includes a table of patients at risk for each time point, showing decreasing patient numbers over 30 months.*
FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 153 2)

FDA Label Image

Image (0c1baa15 83bb 45a0 A3ab 855a4fee9129 175 2)

FDA Label Image

Pemetrexed For Injection, 100mg/vial- Container Label (0c1baa15 83bb 45a0 A3ab 855a4fee9129 10)

Pemetrexed For Injection, 100mg/vial- Container Label (0c1baa15 83bb 45a0 A3ab 855a4fee9129 10)
Label for Pemetrexed for Injection 100 mg/vial, a sterile single-dose intravenous injection powder by Avyxa Pharma LLC. The label includes a warning about its hazardous drug status and ingredient details. Manufactured by Avyxa Pharma in New Jersey, USA.*
FDA Label Image

Pemetrexed For Injection, 100mg/vial- Carton Label (0c1baa15 83bb 45a0 A3ab 855a4fee9129 11)

Pemetrexed For Injection, 100mg/vial- Carton Label (0c1baa15 83bb 45a0 A3ab 855a4fee9129 11)
Pemetrexed for Injection 100 mg vial lyophilized powder packaging label. The label states the product is for intravenous use only and is a sterile single-dose vial. It includes storage instructions, manufacturer Avyxa Pharma, LLC, and cautions about the hazardous drug status. The label also provides reconstitution and dosage preparation guidance, batch details with barcode, and the NDC number 83831-111-01.*
FDA Label Image

Pemetrexed For Injection, 500mg/vial- Container Label (0c1baa15 83bb 45a0 A3ab 855a4fee9129 12)

Pemetrexed For Injection, 500mg/vial- Container Label (0c1baa15 83bb 45a0 A3ab 855a4fee9129 12)
Label for Pemetrexed for Injection 500 mg/vial, lyophilized powder for intravenous use. The sterile single-dose vial is manufactured by Avyxa Pharma, LLC, New Jersey, USA, and made in India. The label includes storage instructions and a barcode.*
FDA Label Image

Pemetrexed For Injection, 500mg/vial- Carton Label (0c1baa15 83bb 45a0 A3ab 855a4fee9129 13)

Pemetrexed For Injection, 500mg/vial- Carton Label (0c1baa15 83bb 45a0 A3ab 855a4fee9129 13)
Packaging label for Pemetrexed for Injection 500 mg/vial, lyophilized powder for intravenous solution, manufactured by Avyxa Pharma, LLC. The label includes drug composition details, reconstitution instructions, storage information, and a barcode. The vial is a sterile, single-dose container with a pink and purple design highlight.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.